Jose Luis Guerrero-Naranjo, MD (Mexico City, Mexico), Hugo Quiroz-Mercado, MD (Mexico City, Mexico), Virgilio Morales- Canton, MD (Mexico City, Mexico), Jans Fromow-Guerra, MD, PhD (Mexico City, Mexico), Griselda Alvarez-Rivera, MD (Mexico City,Mexico), Adriana Solis-Vivanco, MD (Mexico City, Mexico), Elizabeth Reyna-Castelan, MD (Mexico City, Mexico), Maura Abraham, MD (Mexico City, Mexico), Juan Manuel Jimenez-Sierra, MD (Mexico City, Mexico), Myrian Hernandez, MD (Mexico City, Mexico),Orlando Ustariz-Gonzalez, MD (Mexico City, Mexico)

PURPOSE:

Evaluate visual results and changes in macular thickness measured by optical coherence tomography (OCT) in patients diagnosed with macular edema secondary to vein occlusions, treated with intravitreal Bevacizumab.

METHODS:

Case serie, prospective and experimental pilot study. 15 eyes diagnosed with vein occlusion, 11 with branch vein occlusions (BVO) and 4 with central retinal vein occlusion (CRVO), were treated with 0.1ml (1.25mg) intravitreal bevacizumab and followed up during 3 months with best-corrected visual acuity, OCT, and fluorescein angiography.

RESULTS:

Best-corrected visual acuity mean at baseline was 20/400 which improve to 20/100 during the first month and 20/60 on the third month follow-up (p=0.001, Wilcoxon Signed Rank Test). Baseline macular thickness mean was 334.60+ 145.28 μm which decreased to 223.40+ 110.89 μm (p=0.007, Wilcoxon Signed Rank Test) after the first month. There were no ocular or systemic adverse events identified.

CONCLUSION:

Intravitreal bevacizumab is a safe and effective therapy for patients with vein occlusions. The three month follow-up showed a statistically significant improvement in visual acuity, OCT, and angiographic outcomes.